Press Releases BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Real-time Estimate Tradegate Other stock markets 08:30:06 2024-06-18 EDT			5-day change	1st Jan Change
11.25 ^EUR	-0.44%		-4.35%	-11.29%

06-17	BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index	CI
06-14	BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	06-17	AQ
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	06-14	BU
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region	06-13	BU
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	06-04	BU
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	05-28	AQ
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	05-24	BU
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	05-14	BU
BeiGene Reports First Quarter 2024 Financial Results and Business Updates	05-08	BU
BeiGene : Financial Information - Form 8-K	04-26	PU
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report	04-26	BU
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting	04-24	BU
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	04-23	BU
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy	03-15	AQ
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	03-14	BU
First Doses of BRUKINSA provided to Patients with Chronic Lymphocytic Leukemia in Low and Middle-Income Countries under Collaboration of the Max Foundation, BeiGene, and the BeiGene Foundation	03-14	AQ
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation	03-13	BU
BRINGING LIGHT TO THE DARKNESS OF CANCER, BEIGENE NAMED NATIONAL PARTNER OF SURVIVORSHIP AND HOPE FOR THE LEUKEMIA & LYMPHOMA SOCIETY'S LIGHT THE NIGHT	03-13	AQ
BeiGene : Material Event - Form 8-K	03-08	PU
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma	03-07	BU
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024	03-06	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Press Releases

Filters